Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept

Financial Results, Agreements, Meetings, and Clinical Trials - Research Report
   on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad
                               Pharmaceuticals

PR Newswire

NEW YORK, November 20, 2013

NEW YORK, November 20, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom

Today, Analysts' Corner announced new research reports highlighting Cell
Therapeutics, Inc. (NASDAQ: CTIC), Akorn, Inc. (NASDAQ: AKRX), Ligand
Pharmaceuticals Incorporated (NASDAQ: LGND), Intercept Pharmaceuticals, Inc.
(NASDAQ: ICPT), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

Cell Therapeutics, Inc. Research Report

On November 15, 2013, Cell Therapeutics, Inc. (Cell Therapeutics) along with
Baxter International Inc. (Baxter) announced that the two have entered into an
exclusive worldwide licensing agreement to develop and commercialize
pacritinib - a novel investigational JAK2/FLT3 inhibitor with activity against
genetic mutations linked to myelofibrosis, leukemia, and certain solid tumors.
Cell Therapeutics stated that under the terms of the agreement, Baxter gains
exclusive commercialization rights for all indications for pacritinib outside
the U.S., and the Company will commercialize pacritinib in the U.S. together
with Baxter. Commenting on the agreement, James A. Bianco, M.D. President and
CEO of Cell Therapeutics stated, "We believe Baxter represents the ideal
strategic partner to achieve the full potential of pacritinib. Our two
companies share a dedication to oncology and a vision for bringing this unique
oral JAK2/FLT3 inhibitor to patients with certain blood cancers and solid
tumors. This collaboration will provide additional financial resources and
commercial expertise to position us to pursue the development,
commercialization and market potential of pacritinib." The Full Research
Report on Cell Therapeutics, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/f9df_CTIC

--

Akorn, Inc. Research Report

On November 6, 2013, Akorn, Inc. (Akorn) announced that the Company will be
participating at the Midyear Clinical Meeting of American Society of
Heath-System Pharmacists (ASHP), to be held from December 2 to December 6,
2013 in Las Vegas, Nevada. The Company informed that ASHP's Midyear Clinical
Meeting is the largest gathering of pharmacists in the world that focuses on
improving patient care and medication safety, and is attended by over 20,000
pharmacy professionals from about 100 countries. Full Research Report on
Akorn, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/900c_AKRX

--

Ligand Pharmaceuticals Incorporated Research Report

On November 12, 2013, Ligand Pharmaceuticals Incorporated (Ligand) announced
the commencement of a Phase 1 clinical trial with the Company's glucagon
receptor antagonist LGD-6972 for the treatment of type 2 diabetes. Ligand
stated that the randomized double-bind trial is designed to evaluate the
safety and tolerability of ascending single oral doses of LGD-6972 in healthy
subjects and in subjects with type 2 diabetes. Matthew W. Foehr, Executive
Vice President and COO of Ligand, commented, "We believe glucagon receptor
antagonism holds an important potential in the treatment and management of
type 2 diabetes. We are excited to begin this Phase 1 study with this novel
drug, and look forward to evaluating results in 2014. LGD-6972 is a
significant unpartnered asset of Ligand, as approximately 350 million people
have diabetes worldwide. The market for diabetes drugs is projected to exceed
$60 billion by 2020." The Full Research Report on Ligand Pharmaceuticals
Incorporated - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3b8d_LGND

--

Intercept Pharmaceuticals, Inc. Research Report

On November 14, 2013, Intercept Pharmaceuticals, Inc. (Intercept
Pharmaceuticals) reported its financial results for Q3 2013. Licensing revenue
for Q3 2013 was down by 22.6% YoY to $0.4 million. Net loss attributable to
common stockholders for the quarter was $31.7 million, or $1.65 per diluted
share, compared to net loss attributable to common stockholders of $6.2
million or $1.86 per diluted share in Q3 2012. Intercept Pharmaceuticals
stated that with effect from October 1, 2013, it has extended the term of its
research program with Servier relating to the discovery of novel TGR5 agonists
until September 30, 2015. The Company also announced that its CEO, Mark
Pruzanski, M.D, will be presenting at the following upcoming investor
conferences: Jefferies 2013 London Healthcare Conference on November 21, 2013
at 8:40 a.m. GMT; 2013 Deutsche Bank BioFEST on December 3, 2013, at 11:20
a.m. ET; and Oppenheimer 24^th Annual Healthcare Conference on December 10,
2013, at 3:20 p.m. ET. The Full Research Report on Intercept Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b477_ICPT

--

Ariad Pharmaceuticals Inc. Research Report

On November 12, 2013, Ariad Pharmaceuticals Inc. (Ariad) reported its Q3 2013
financial results. In addition, the Company also announced the actions it is
taking to reduce cash used in operations over the next two years and to better
align its resources to areas of narrowed strategic focus. During Q3 2013,
total revenues were $16.7 million, compared to $85,000 in Q3 2012. Net loss
was $66.3 million or $0.36 per diluted share during the quarter, compared to
$53.2 million or $0.32 per diluted share in Q3 2012. Ariad Chairman and CEO
Harvey J. Berger, M.D., stated, "Following recent corporate developments, we
have taken swift action to significantly reduce operating expenses and extend
our cash runway. Additionally, we have refocused and reprioritized our
investments around near-term, shareholder-value creating activities." The Full
Research Report on Ariad Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/161c_ARIA

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.